Oncoflour 250mg Injection Vial

babies: not applicable. lactating mothers: it is unsafe to use this medicine during breastfeeding. studies have shown that the drug causes harmful effects on the baby. pregnancy: it is unsafe to use this medicine during pregnancy.
human studies have shown that the drug causes harmful effects on the developing baby. seek the doctor's advice before using this medicine. alcohol: information about the consumption of alcohol while taking this medicine is limited.
please consult your doctor before taking this medicine. driving: this medicine causes nausea and visual changes. do not drive if you experience the symptoms that alter your ability to drive.
kidney: it is safe to use this medicine in patients with kidney disease. dose adjustment is not required.
seek a doctor's advice before taking this medicine. liver: this medicine should be, used with caution in patients with liver disease. dose adjustment is required.
seek a doctor's advice before using this medicine..

increased risk of infection mouth ulcer vomiting weakness nausea loss of appetite hair loss blisters on fingers or feet diarrhoea.

oncoflour injection is an antineoplastic medication used in the treatment of cancer. it works by inhibiting the growth of genetic material of the cancer cells and prevents the multiplication of cancer cells..

consult your doctor immediately if you missed the dose of oncoflour injection..

• take this medicine as prescribed by your doctor. • do not stop taking this medicine suddenly without informing your doctor. • if you experience blisters on your fingers or feet, hair loss, decreased blood cells, mouth ulcers, and weakness while taking this medicine, inform your doctor. • go for blood cell and liver function tests while taking this medicine regularly. • do not drive while taking this medicine as it causes dizziness and visual changes..

major • oncoflour + adalimumab: concurrent use of these medicines lead to an increase in the risk of life-threatening infections • oncoflour + baricitinib: concurrent use of these medicines lead to an increase in the risk of life-threatening infections • oncoflour + certolizumab: concurrent use of these medicines lead to an increase in the risk of life-threatening infections • oncoflour + dicumarol: concurrent use of these medicines lead to unusual bleeding • oncoflour + etanercept: concurrent use of these medicines lead to an increase in the risk of life-threatening infections moderate • oncoflour + azathioprine: concurrent use of these medicines lead to an increase in the risk of life-threatening infections • oncoflour + carboplatin: concurrent use of these medicines lead to an increase in the risk of bone marrow and gastrointestinal infections • oncoflour + dactinomycin: concurrent use of these medicines lead to an increase in the risk of bone marrow and gastrointestinal infections • oncoflour + doxorubicin: concurrent use of these medicines lead to an increase in the risk of bone marrow and gastrointestinal infections • oncoflour + epirubicin: concurrent use of these medicines lead to an increase in the risk of bone marrow and gastrointestinal infections.